Versant Venture Capital VII L.P. 13D and 13G filings for Chinook Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-03-10 4:13 pm Sale | 2023-03-01 | 13D | Chinook Therapeutics, Inc. KDNY | Versant Venture Capital VII L.P. | 2,105,107 3.200% | -240,000 (-10.23%) | Filing |
| 2022-12-28 4:07 pm Sale | 2022-12-22 | 13D | Chinook Therapeutics, Inc. KDNY | Versant Venture Capital VII L.P. | 2,345,107 3.700% | -567,963 (-19.50%) | Filing |
| 2022-08-22 4:15 pm Unchanged | 2022-08-12 | 13D | Chinook Therapeutics, Inc. KDNY | Versant Venture Capital VII L.P. | 2,913,070 4.600% | 0 (Unchanged) | Filing |
| 2022-04-13 4:43 pm Sale | 2022-04-04 | 13D | Chinook Therapeutics, Inc. KDNY | Versant Venture Capital VII L.P. | 2,913,070 5.300% | -709,953 (-19.60%) | Filing |
| 2022-01-13 4:30 pm Sale | 2022-01-03 | 13D | Chinook Therapeutics, Inc. KDNY | Versant Venture Capital VII L.P. | 3,623,023 6.700% | -600,000 (-14.21%) | Filing |
| 2021-09-07 5:13 pm Sale | 2021-08-27 | 13D | Chinook Therapeutics, Inc. KDNY | Versant Venture Capital VII L.P. | 4,223,023 9.400% | -510,000 (-10.78%) | Filing |
| 2020-10-15 5:16 pm Purchase | 2020-10-05 | 13D | Chinook Therapeutics, Inc. KDNY | Versant Venture Capital VII L.P. | 4,733,023 11.200% | 4,733,023 (New Position) | Filing |